Literature DB >> 10501782

Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study.

C E De Laet1, B A van Hout, H Burger, A E Weel, A Hofman, H A Pols.   

Abstract

The aim of this study was to estimate the additional cost of medical care (the incremental cost) caused by incident hip and vertebral fractures, using a matched case cohort design within a longitudinal follow-up study. Incident hip fractures were recorded using the regular follow-up system of the Rotterdam Study. Incident vertebral fractures were recorded by morphometric comparison of spinal radiographs taken at intervals of 2.2 years on average. The matched control group was randomly selected from other participants of the Rotterdam Study in whom no fracture occurred during follow-up, but who were otherwise comparable at baseline. Cases were matched for age, gender, self-perceived health, ability to perform activities of daily life, living situation and general practitioner. Medical expenditure was assessed by retrieval of the general practice medical records and by recording all hospital and nursing home admissions, and all general practice and outpatient visits. Pharmaceutical consumption was recorded through the computerized records of the central pharmacy. Valid results were obtained for 44 pairs (91%) in the hip fracture and for 42 pairs (93%) in the vertebral fracture group. Cost of medical consumption in the year before the hip fracture was similar in patients and control subjects, but the incremental cost in the first year after the hip fracture was almost US$10 000. In the second year after hip fracture the incremental cost was still about $1000. Accounting for the excess mortality in hip fracture patients had little effect on cost in the first year, but cost in the second year was doubled to almost $2000. For vertebral fractures, we did not detect important acute care costs, but these fractures were associated with a yearly recurrent incremental cost of over $1000. However, almost half this difference was already present before the occurrence of the fracture, and was attributable to hospital admissions. The remainder of the incremental cost was mainly due to pharmaceutical consumption and to a lesser extent to admissions to orthopedic surgery wards. We conclude that hip fractures cause excess mortality and an important incremental cost especially during the first year, and that these could probably be avoided by prevention of hip fractures. For vertebral fractures we found no evidence of important acute care costs but we observed a yearly returning incremental cost. Part of this incremental cost, however, was pre-existing and might therefore by caused by co-morbidity.

Entities:  

Mesh:

Year:  1999        PMID: 10501782     DOI: 10.1007/s001980050196

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  29 in total

1.  Mortality within 1 year after hip fracture surgical repair in the elderly according to postoperative period: a probabilistic record linkage study in Brazil.

Authors:  E I O Vidal; C M Coeli; R S Pinheiro; K R Camargo
Journal:  Osteoporos Int       Date:  2006-07-27       Impact factor: 4.507

2.  Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.

Authors:  Fredrik Borgström; Olof Johnell; John A Kanis; Anders Oden; David Sykes; Bengt Jönsson
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Determinants of health-related quality of life in women with vertebral fractures.

Authors:  Alexandra Papaioannou; Courtney C Kennedy; George Ioannidis; Jacques P Brown; Anjali Pathak; David A Hanley; Robert G Josse; Rolf J Sebaldt; Wojciech P Olszynski; Alan Tenenhouse; Timothy M Murray; Annie Petrie; Charles H Goldsmith; Jonathan D Adachi
Journal:  Osteoporos Int       Date:  2005-12-09       Impact factor: 4.507

Review 4.  Hip fracture prevention: cost-effective strategies.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  The Amsterdam Hip Protector Study: compliance and determinants of compliance.

Authors:  N M van Schoor; G Asma; J H Smit; L M Bouter; P Lips
Journal:  Osteoporos Int       Date:  2003-04-18       Impact factor: 4.507

6.  The hospital cost of vertebral fractures in the EU: estimates using national datasets.

Authors:  Henrik W Finnern; David P Sykes
Journal:  Osteoporos Int       Date:  2003-04-30       Impact factor: 4.507

7.  Cost-effectiveness of hip protectors in frail institutionalized elderly.

Authors:  Natasja M van Schoor; Martine C de Bruyne; Nicole van der Roer; Els Lommerse; Maurits W van Tulder; Lex M Bouter; Paul Lips
Journal:  Osteoporos Int       Date:  2004-04-22       Impact factor: 4.507

Review 8.  Economic implication of osteoporotic spine disease: cost to society.

Authors:  Olof Johnell
Journal:  Eur Spine J       Date:  2003-09-19       Impact factor: 3.134

9.  Direct healthcare costs for 5 years post-fracture in Canada: a long-term population-based assessment.

Authors:  W D Leslie; L M Lix; G S Finlayson; C J Metge; S N Morin; S R Majumdar
Journal:  Osteoporos Int       Date:  2013-01-23       Impact factor: 4.507

10.  Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures.

Authors:  Lucinda Strycker Orsini; Matthew D Rousculp; Stacey R Long; Shaohung Wang
Journal:  Osteoporos Int       Date:  2004-09-01       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.